Display options
Cite
Haass-Koffler CL, Leggio L, Davidson D, et al. Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study. Alcohol Clin Exp Res. 2015;39(4):594-602doi: 10.1111/acer.12658.
Haass-Koffler, C. L., Leggio, L., Davidson, D., & Swift, R. M. (2015). Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study. Alcoholism, clinical and experimental research, 39(4), 594-602. https://doi.org/10.1111/acer.12658
Haass-Koffler, Carolina L, et al. "Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study." Alcoholism, clinical and experimental research vol. 39,4 (2015): 594-602. doi: https://doi.org/10.1111/acer.12658
Haass-Koffler CL, Leggio L, Davidson D, Swift RM. Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study. Alcohol Clin Exp Res. 2015 Apr;39(4):594-602. doi: 10.1111/acer.12658. PMID: 25833022; PMCID: PMC4384190.
Copy Download .nbib Format: NLM
Share it on

Alcohol Clin Exp Res. 2015 Apr;39(4):594-602. doi: 10.1111/acer.12658.

Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.

Alcoholism, clinical and experimental research

Carolina L Haass-Koffler, Lorenzo Leggio, Dena Davidson, Robert M Swift

Affiliations

  1. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island.

PMID: 25833022 PMCID: PMC4384190 DOI: 10.1111/acer.12658

Abstract

BACKGROUND: Preliminary basic and human studies suggest that the α2 -adrenergic antagonist idazoxan may represent a novel medication for alcohol dependence. The goal of this study was to evaluate the safety and tolerability of the co-administration of idazoxan with alcohol and explore whether pharmacokinetics (PK) and biobehavioral mechanisms of idazoxan may alter alcohol's effects.

METHODS: This was a preliminary double-blind, single-dose, placebo-controlled, crossover, randomized human laboratory study. Ten social drinkers were dosed, in 2 different alcohol challenge studies (ACS), with a single oral dose of idazoxan (40 mg) or placebo, followed by a fixed alcohol dose 60 minutes later. Participants returned after a 1-week washout, and they were crossed over to the opposite medication condition.

RESULTS: There were no significant differences in adverse events between idazoxan and placebo. Moreover, during the ACS paradigm, 40 mg idazoxan was well tolerated with no significant autonomic effects compared to placebo; idazoxan reduced the peak blood alcohol level (p < 0.01) and time to peak (p < 0.05) compared to placebo. A PK/pharmacodynamic model aligned the biobehavioral effects, demonstrating that the co-administration of 40 mg idazoxan with alcohol decreased alcohol-related stimulation (p < 0.05) and increased alcohol-related sedation (p < 0.05).

CONCLUSIONS: This study supports the safety and tolerability of 40 mg idazoxan when co-administered with alcohol. Additionally, this study suggests that idazoxan may alter the biphasic effects of alcohol by decreasing stimulation and increasing sedation. These findings have implications for further investigation of using idazoxan as a probe to develop potential novel medications to treat alcoholic patients.

Copyright © 2015 by the Research Society on Alcoholism.

Keywords: Alcohol Challenge Study; Idazoxan; Norepinephrine; PK/PD Alcohol Model

References

  1. Neurosci Lett. 1977 Sep;5(6):333-6 - PubMed
  2. Alcohol Clin Exp Res. 2013 Feb;37(2):202-12 - PubMed
  3. Eur J Clin Pharmacol. 1986;29(6):743-5 - PubMed
  4. JAMA. 1984 Oct 12;252(14):1905-7 - PubMed
  5. Alcohol Health Res World. 1997;21(2):144-8 - PubMed
  6. Br J Clin Pharmacol. 1994 May;37(5):427-31 - PubMed
  7. Hum Psychopharmacol. 2011 Dec;26(8):554-9 - PubMed
  8. Clin Pharmacol Ther. 1983 Aug;34(2):143-7 - PubMed
  9. Alcohol Clin Exp Res. 2008 Dec;32(12):2074-80 - PubMed
  10. Br J Pharmacol. 1983 Mar;78(3):489-505 - PubMed
  11. Life Sci. 1989;44(2):111-9 - PubMed
  12. Am J Psychiatry. 1994 Oct;151(10):1463-7 - PubMed
  13. Br J Clin Pharmacol. 2002 Dec;54(6):587-91 - PubMed
  14. Eur J Pharmacol. 1989 Aug 3;166(3):381-6 - PubMed
  15. Neuropharmacology. 1989 Mar;28(3):275-81 - PubMed
  16. Psychopharmacology (Berl). 1989;97(2):189-93 - PubMed
  17. Alcohol Clin Exp Res. 2000 Jun;24(6):802-9 - PubMed
  18. Clin Pharmacol Ther. 1979 Mar;25(3):358-71 - PubMed
  19. J Occup Med. 1985 Mar;27(3):206-12 - PubMed
  20. Alcohol. 1985 Mar-Apr;2(2):339-42 - PubMed
  21. Fundam Clin Pharmacol. 2014 Jun;28(3):284-93 - PubMed
  22. Psychopharmacology (Berl). 2013 Mar;226(1):65-73 - PubMed
  23. Psychopharmacology (Berl). 1995 Mar;118(2):127-35 - PubMed
  24. Alcohol Alcohol. 1996 Mar;31 Suppl 1:77-81 - PubMed
  25. Alcohol Clin Exp Res. 2012 Feb;36(2):351-60 - PubMed
  26. Eur J Pharmacol. 2010 Jul 10;637(1-3):89-101 - PubMed
  27. J Pharm Pharmacol. 1966 Dec;18(12):821-3 - PubMed
  28. J Stud Alcohol. 1975 Jan;36(1):117-26 - PubMed
  29. Drugs Exp Clin Res. 1996;22(1):17-24 - PubMed
  30. Arch Gen Psychiatry. 2011 Apr;68(4):389-99 - PubMed
  31. J Neurosci. 2000 May 1;20(9):3157-64 - PubMed
  32. Pharmacol Biochem Behav. 2002 May;72(1-2):151-6 - PubMed
  33. Biol Pharm Bull. 2003 Mar;26(3):368-70 - PubMed
  34. Clin Pharmacokinet. 1997 Aug;33(2):79-90 - PubMed
  35. J Psychopharmacol. 1991 Jan;5(4):396-403 - PubMed
  36. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):586-91 - PubMed
  37. Br J Clin Pharmacol. 2011 Jun;71(6):815-23 - PubMed
  38. Alcohol Clin Exp Res. 1993 Feb;17(1):140-6 - PubMed
  39. Behav Res Ther. 1980;18(1):37-43 - PubMed
  40. Psychopharmacology (Berl). 1992;108(3):313-9 - PubMed
  41. Science. 1982 Mar 12;215(4538):1394-6 - PubMed
  42. Alcohol Clin Exp Res. 1994 Aug;18(4):873-8 - PubMed
  43. Trends Pharmacol Sci. 1992 Jul;13(7):277-82 - PubMed
  44. JAMA. 2014 May 14;311(18):1889-900 - PubMed
  45. Alcohol. 2014 Sep;48(6):543-9 - PubMed
  46. Int J Clin Pharmacol Ther. 1997 Oct;35(10):465-8 - PubMed
  47. CNS Drugs. 2014 Apr;28(4):343-60 - PubMed
  48. J Pharmacol Exp Ther. 1996 Nov;279(2):443-9 - PubMed
  49. Naunyn Schmiedebergs Arch Pharmacol. 1984 Feb;325(2):136-44 - PubMed

Substances

MeSH terms

Publication Types

Grant support